AN2 Therapeutics
Menlo Park, United States · Biotechnology, Health Care, Science And Engineering
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM lung disease caused by M. abscessus and melioidosis,, along with programs focused on targets in oncology and infectious diseases. We are committed t
Key facts
- Headquarters
- Menlo Park, United States
- Employees
- 36
- Industries
- Biotechnology, Health Care, Science And Engineering
- Status
- Public (ANTX)
- Website
- an2therapeutics.com
- Company page
Recent activity at AN2 Therapeutics
- : AN2 Therapeutics Appoints Cameron Trenor, M.D. as Chief Medical Officer
- : AN2 Therapeutics secures $40 million in Private Equity financing to support its development of novel therapeutics, led by Coastlands Capital and others.
- : AN2 Therapeutics Appoints Sarah Williams as New Vice President, Controller
- : SEC 8-K (8.01):
- : SEC 8-K (8.01): On April 9, 2026, AN2 Therapeutics, Inc. terminated its previous Sales Agreement with TD Cowen, effective immediately, which had been in place since April 6, 2023. Under this agreement, the Company had sold 2,502,000 shares of its common stock for an aggregate amount of $20,016,251. Concurrently, the Company entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the issuance and sale of up to $80 million of common stock, which will be sold on an 'at the market' basis. This strategic move may enhance the Company's capital raising efforts while providing Jefferies a commission of up to 3% on the gross proceeds from sales. The conditions of the new agreement stipulate that it will terminate upon the sale of all shares or a ten-day notice of termination by either party.
- : SEC 8-K (5.02): On March 19, 2026, AN2 Therapeutics, Inc. approved a stock option repricing under the Amended and Restated 2017 Equity Incentive Plan and the 2022 Equity Incentive Plan. This Option Repricing reduced the exercise price of all outstanding stock options held by named executive officers and non-employee Board members to $3.91 per share, the closing stock price on the Repricing Date. The amendment includes a Premium End Date, which could trigger additional terms concerning the options. Named executive officers, including CEO Eric Easom, hold a total of 1,106,764 Eligible Options. This repricing aims to enhance retention and motivation among executive participants without excessive dilution from new equity grants or cash expenditures. The decision reflects the Board's belief that the repricing aligns with the Company’s best interests.
- : SEC 8-K (1.01): On March 8, 2026, AN2 Therapeutics, Inc. entered into a Securities Purchase Agreement with certain investors, providing for the sale and issuance of 8,245,611 shares of common stock at a price of $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares of common stock. The total gross proceeds from this Private Placement are expected to be approximately $40 million. The closing of this transaction is projected to occur on March 10, 2026. The pre-funded warrants have an exercise price of $0.00001 and include beneficial ownership limitations which prevent holders from exercising if it would result in beneficial ownership exceeding 9.99% of the company's outstanding shares without prior notice.
- : SEC 8-K (5.02): On January 26, 2026, AN2 Therapeutics, Inc. appointed Sarah Williams as Vice President, Controller, and Principal Accounting Officer, effective February 1, 2026. Ms. Williams previously served as Corporate Controller since May 2024 and has a rich background in finance from roles at Gritstone Bio and other firms. Her compensation package includes an annual base salary of $310,000 and eligibility for a 30% bonus. Additionally, the Company amended an Employment Letter Agreement with Lucy Day, who will continue as CFO, adjusting her salary to $335,400 effective immediately through March 2026.
- : SEC 8-K (5.02): On January 26, 2026, AN2 Therapeutics, Inc. appointed Sarah Williams as Vice President, Controller, and Principal Accounting Officer, effective February 1, 2026. This appointment follows Lucy Day's continued role as Chief Financial Officer and Principal Financial Officer. Ms. Williams has been with AN2 Therapeutics since May 2024 and previously worked at Gritstone Bio and Bio-Rad Laboratories, showcasing her extensive experience in the biotechnology sector. The strategic appointment is aimed at strengthening the financial leadership of the company as it continues to grow.
- : An2 Therapeutics Closed $80 Million Series B Financing To Advance Novel Nontuberculous Mycobacterial Lung Disease Program
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
AN2 Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Post-IPO Equity | $40.0M |
| Jan 2022 | Series B | $80.0M |
Leadership
- Cameron Trenor, M.D., Chief Medical Officer
- Sarah Williams, Vice President
Verified email and direct lines for AN2 Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
AN2 Therapeutics in the news
- AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - Business Wire (May 21, 2026)
- AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - BioSpace (Mar 04, 2026)
- AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK - Business Wire (Sep 28, 2026)
- AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) - Business Wire (Oct 23, 2026)
- AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18 - Business Wire (Oct 21, 2026)
- AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera - Business Wire (Nov 02, 2026)
- AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Business Wire (Aug 31, 2026)
- AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights - Business Wire (Aug 11, 2026)
Companies similar to AN2 Therapeutics
- Electra Therapeutics · Biotechnology, Health Care, Science And Engineering
- PineTree Therapeutics · Biotechnology, Health Care, Science And Engineering
- Saol Therapeutics · Biotechnology, Health Care, Science And Engineering
- Atavistik Bio · Biotechnology, Health Care, Science And Engineering
- Ray Therapeutics · Biotechnology, Health Care, Science And Engineering
About AN2 Therapeutics: questions and answers
What does AN2 Therapeutics do?
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM lung disease caused by M. abscessus and melioidosis,, along with programs focused on targets in oncology and infectious diseases. We are committed t
Where is AN2 Therapeutics headquartered?
AN2 Therapeutics is headquartered in Menlo Park, United States.
How many employees does AN2 Therapeutics have?
AN2 Therapeutics has about 36 employees.
Has AN2 Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for AN2 Therapeutics. The most recent, Post-IPO Equity of $40.0M, was in Mar 2026.
Who leads AN2 Therapeutics?
Sarah Williams is a Vice President at AN2 Therapeutics.
What is the latest news on AN2 Therapeutics?
On Aug 24, 2026, AN2 Therapeutics Appoints Cameron Trenor, M.D. as Chief Medical Officer
Is AN2 Therapeutics a public company?
Yes. AN2 Therapeutics is publicly traded under the ticker ANTX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy